Last updated: February 20, 2026
What Is NDC 00955-1720?
NDC 00955-1720 corresponds to Bevacizumab (brand name Avastin), a monoclonal antibody used in oncology, ophthalmology, and certain vascular conditions. Its primary indications include metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and age-related macular degeneration (AMD).
Market Overview
Global Market Size
The global bevacizumab market was valued at approximately USD 8.2 billion in 2021. It is projected to reach USD 12.5 billion by 2028, growing at a compound annual growth rate (CAGR) of approximately 6.2% from 2022 to 2028 [1].
Market Drivers
- Increased cancer prevalence: Globally, cancer incidence is rising, especially in developing regions.
- Expanding indications: Key approvals for multiple cancers and eye diseases broaden usage.
- Biosimilar entry: Patent expirations stimulate price competition, influencing market dynamics.
Competitive Landscape
Major manufacturers include Genentech (a Roche subsidiary), Amgen, and Samsung Bioepis (biosimilars). Biosimilars entered the market in late 2020, offering alternatives that impact pricing.
Price Analysis & Projections
Current Pricing
- Brand Name (Avastin): Wholesale acquisition cost (WAC) for a 100 mg vial hovers around USD 1,500–1,700.
- Biosimilars: Prices range from USD 800–1,200 per 100 mg vial, a significant reduction.
Historical Price Trends
Since patent expiry in 2018 for certain formulations, prices have declined by 20–30% as biosimilars entered the market. The trend indicates further reductions as biosimilar penetration deepens.
Future Price Projections (2023–2028)
| Year |
Estimated Price for 100 mg vial (USD) |
Notes |
| 2023 |
800–1,000 |
Continued biosimilar competition; slight price stabilization. |
| 2024 |
750–950 |
Increased biosimilar market share; possible price decrease. |
| 2025 |
700–900 |
Market saturation; price stabilization expected. |
| 2026 |
650–850 |
Potential new biosimilar entrants; further price pressure. |
| 2027 |
600–800 |
Market equilibrium with multiple biosimilar options. |
| 2028 |
600–800 |
Prices stabilize around current biosimilar margins. |
Factors Influencing Future Pricing
- Market penetration of biosimilars: Higher adoption reduces average prices.
- Regulatory landscape: Approvals of new biosimilar formulations or indications.
- Healthcare policies: Value-based pricing models may further pressure costs.
- Reimbursement policies: Payers' willingness to favor biosimilars impacts retail prices.
Outlook and Strategic Considerations
- Market saturation: The high number of biosimilars in the pipeline will pressurize prices further.
- Therapeutic innovations: Novel therapies, such as immune checkpoint inhibitors, could influence bevacizumab’s market share.
- Regulatory risk: Changes in patent protection or biosimilar approval pathways could alter competitiveness.
Key Takeaways
- The market for NDC 00955-1720 (bevacizumab) is highly competitive, dominated by biosimilars.
- Prices are trending downward, with projections suggesting stabilization at lower levels over the next five years.
- The market growth remains robust mainly due to expanding indications and aging populations.
- Price pressures will intensify with biosimilar market penetration and evolving reimbursement policies.
FAQs
1. What are the primary indications for NDC 00955-1720?
It is used to treat various cancers (colorectal, lung, glioblastoma) and eye diseases like AMD.
2. How have biosimilars impacted the market price?
Biosimilars introduced in late 2020 have reduced prices by approximately 20–30%, with ongoing competition expected to lower costs further.
3. What factors could increase the price of bevacizumab?
Innovations leading to new indications, improved formulations, or regulatory barriers delaying biosimilar approvals could increase prices temporarily.
4. Who are the main players in the bevacizumab biosimilar market?
Amgen, Samsung Bioepis, and Celltrion are key biosimilar manufacturers competing with originator Genentech.
5. How might future healthcare policies influence bevacizumab's market prices?
Pricing and reimbursement models promoting value-based care and biosimilar substitution will likely continue to exert downward pressure.
References
[1] MarketWatch. (2022). Bevacizumab Market Size, Share & Trends Analysis. Retrieved from https://www.marketwatch.com
